Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.
Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 3, 3, 9, 6, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Neutropenia - Overview
Chemotherapy Induced Neutropenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
Apotex Inc
BeyondSpring Inc
Biocon Ltd
Biosimilar Solutions LLC
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
CSPC Pharmaceutical Group Ltd
Curateq Biologics Pvt Ltd
Dr. Reddy's Laboratories Ltd
Enzychem Lifesciences Corp
Evive Biotech
FortuneRock (China) Ltd
General Regeneratives Shanghai Ltd
GlycoMimetics Inc
Hangzhou Jiuyuan Gene Engineering Co Ltd
Hanmi Pharmaceuticals Co Ltd
Ilkogen Ilac San Ve Tic AS
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Karyo Biologics LLC
Kidswell Bio Corp
Ligand Pharmaceuticals Inc
Lupin Ltd
Mabwell Shanghai Bioscience Co Ltd
Mycenax Biotech Inc
Pangen Biotech Inc
Profarma
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Siam Bioscience Co Ltd
Tanvex BioPharma Inc
UBI Pharma Inc
USV Pvt Ltd
Valenta Pharm
Xiamen Amoytop Biotech Co Ltd
Chemotherapy Induced Neutropenia - Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BBT-015 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
efbemalenograstim alfa LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
eflapegrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgrastim - Drug Profile
Product Description
Mechanism Of Action
filgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgrastim - Drug Profile
Product Description
Mechanism Of Action
filgrastim - Drug Profile
Product Description
Mechanism Of Action
filgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgrastim - Drug Profile
Product Description
Mechanism Of Action
filgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
GR-007 - Drug Profile
Product Description
Mechanism Of Action
GW-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GXG-3 - Drug Profile
Product Description
Mechanism Of Action
History of Events
imidazolyl ethanamide pentandioic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
lenograstim - Drug Profile
Product Description
Mechanism Of Action
LG-7455 - Drug Profile
Product Description
Mechanism Of Action
mosedipimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
pegfilgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
plinabulin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize GCSFR for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
History of Events
SFR-9314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UB-853 - Drug Profile
Product Description
Mechanism Of Action
uproleselan sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
YPEG-Filgrastim - Drug Profile
Product Description
Mechanism Of Action
History of Events
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Featured News & Press Releases
Feb 24, 2022: Yifan Pharma's announcement on the progress of the F-627 Project
Dec 15, 2021: BeyondSpring Pharmaceuticals announces new clinical data confirming plinabulin’s fast onset mechanism of action in the prevention of chemotherapy-induced neutropenia at the 63rd ASH Annual Meeting and Exposition
Dec 10, 2021: BeyondSpring Pharmaceuticals announces analysis of new data on the plinabulin/pegfilgrastim combination in breast cancer at the 2021 San Antonio Breast Cancer Symposium
Dec 01, 2021: BeyondSpring Pharmaceuticals receives complete response letter from the FDA for plinabulin new drug application for prevention of chemotherapy-induced neutropenia (CIN)
Sep 16, 2021: BeyondSpring Pharmaceuticals announces new positive data on plinabulin from its chemotherapy-induced neutropenia prevention program at the European Society for Medical Oncology 2021 Congress
Sep 09, 2021: BeyondSpring announces three poster presentations about its chemotherapy-induced neutropenia prevention program at the European Society for Medical Oncology 2021 Congress
Jun 17, 2021: BeyondSpring to host R&D day to discuss novel immune agent Plinabulin’s development program in anti-cancer indications
Jun 10, 2021: BeyondSpring announces final positive data from the PROTECTIVE-1 phase 3 CIN program of plinabulin as a single agent compared to pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 08, 2021: BeyondSpring announces a late-breaking poster presentation of PROTECTIVE-2 phase 3 data showing plinabulin, in combination with pegfilgrastim, reverses the immune-suppressive effects of pegfilgrastim and offers superior prevention of chemotherapy-induced neutropenia (CIN) at the FOCIS Annual Meeting
Jun 07, 2021: BeyondSpring announces three presentations highlighting positive clinical outcome data from the phase 3 program of plinabulin in combination with pegfilgrastim for the prevention of Chemotherapy-induced neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 02, 2021: Lupin announces U.S. FDA acceptance for Pegfilgrastim biosimilar application
Jun 01, 2021: BeyondSpring announces U.S. FDA acceptance and priority review of new drug application for plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN)
Apr 28, 2021: BeyondSpring announces five presentations at the American Society of Clinical Oncology (ASCO) annual meeting
Mar 31, 2021: Evive Biotech submits biologics license application to US FDA for Ryzneuta
Mar 31, 2021: BeyondSpring announces submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Biosimilar Solutions LLC, 2022
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Curateq Biologics Pvt Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Enzychem Lifesciences Corp, 2022
Chemotherapy Induced Neutropenia - Pipeline by Evive Biotech, 2022
Chemotherapy Induced Neutropenia - Pipeline by FortuneRock (China) Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by General Regeneratives Shanghai Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Hangzhou Jiuyuan Gene Engineering Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Ilkogen Ilac San Ve Tic AS, 2022
Chemotherapy Induced Neutropenia - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Jiangsu T-mab BioPharma Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Karyo Biologics LLC, 2022
Chemotherapy Induced Neutropenia - Pipeline by Kidswell Bio Corp, 2022
Chemotherapy Induced Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by Profarma, 2022
Chemotherapy Induced Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, 2022
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, 2022
Chemotherapy Induced Neutropenia - Pipeline by Siam Bioscience Co Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Tanvex BioPharma Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by UBI Pharma Inc, 2022
Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, 2022
Chemotherapy Induced Neutropenia - Pipeline by Valenta Pharm, 2022
Chemotherapy Induced Neutropenia - Pipeline by Xiamen Amoytop Biotech Co Ltd, 2022
Chemotherapy Induced Neutropenia - Dormant Projects, 2022
Chemotherapy Induced Neutropenia - Dormant Projects, 2022 (Contd..1)
Chemotherapy Induced Neutropenia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
